Insmed reported $765K in Interest Income for its fiscal quarter ending in September of 2024.





Interest Income Change Date
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Cytokinetics USD 13M 700K Jun/2025
DBV Technologies USD -0.32 0.02 Sep/2024
Dynavax Technologies USD 6.8M 941K Jun/2025
Gilead Sciences USD 73M 21M Jun/2025
Insmed USD 765K 55K Sep/2024
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Sarepta Therapeutics USD 7.14M 3.05M Jun/2025
Ultragenyx Pharmaceutical USD 5.79M 1.04M Jun/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025